Rep. Gilbert Ray Cisneros, Jr. Purchases Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on July 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Praxis Precision Medicines Price Performance

Praxis Precision Medicines stock opened at $351.81 on Tuesday. The firm has a market cap of $9.82 billion, a price-to-earnings ratio of -27.21 and a beta of 2.76. Praxis Precision Medicines, Inc. has a 52 week low of $37.19 and a 52 week high of $392.70. The business’s 50-day moving average price is $338.95 and its 200 day moving average price is $323.32.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating the consensus estimate of ($3.67) by $0.80. Equities analysts expect that Praxis Precision Medicines, Inc. will post -13.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PRAX. The Goldman Sachs Group reaffirmed a “buy” rating and set a $575.00 target price (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Monday, August 24th. BTIG Research restated a “buy” rating and set a $810.00 price target on shares of Praxis Precision Medicines in a research report on Wednesday, July 29th. HC Wainwright cut their price objective on shares of Praxis Precision Medicines from $1,245.00 to $1,201.00 and set a “buy” rating for the company in a report on Tuesday, June 2nd. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $462.00 price objective (up from $449.00) on shares of Praxis Precision Medicines in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Praxis Precision Medicines has a consensus rating of “Moderate Buy” and an average price target of $585.95.

Insider Buying and Selling

In other Praxis Precision Medicines news, Director Jill Desimone sold 11,600 shares of the firm’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total value of $3,611,312.00. Following the transaction, the director owned 2,337 shares in the company, valued at approximately $727,554.84. This trade represents a 83.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Praxis Precision Medicines

Several institutional investors have recently modified their holdings of PRAX. California State Teachers Retirement System raised its holdings in shares of Praxis Precision Medicines by 32,314.1% during the second quarter. California State Teachers Retirement System now owns 8,906,418 shares of the company’s stock valued at $2,981,780,000 after acquiring an additional 8,878,941 shares during the last quarter. Orbis Allan Gray Ltd acquired a new stake in shares of Praxis Precision Medicines in the fourth quarter worth approximately $369,946,000. Janus Henderson Group PLC boosted its stake in shares of Praxis Precision Medicines by 17.2% in the fourth quarter. Janus Henderson Group PLC now owns 3,240,086 shares of the company’s stock worth $954,834,000 after acquiring an additional 476,227 shares during the last quarter. Barclays PLC increased its position in shares of Praxis Precision Medicines by 592.6% during the fourth quarter. Barclays PLC now owns 530,751 shares of the company’s stock worth $156,434,000 after purchasing an additional 454,114 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its position in shares of Praxis Precision Medicines by 63.4% during the fourth quarter. Baker BROS. Advisors LP now owns 1,126,488 shares of the company’s stock worth $332,021,000 after purchasing an additional 437,000 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.